Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer ; day:21 ; month:8 ; year:2018 ; pages:1-6
Wiener klinische Wochenschrift ; (21.8.2018), 1-6
- Urheber
-
Asamer, Eva
- Beteiligte Personen und Organisationen
-
Szkandera, Joanna
Gibiser, Paul
Lembeck, Anna Lena
Stojakovic, Tatjana
Kornprat, Peter
Lackner, Caroline
Winder, Thomas
Schlick, Konstantin
Stöger, Herbert
Gerger, Armin
Pichler, Martin
Stotz, Michael
SpringerLink (Online service)
- DOI
-
10.1007/s00508-018-1383-3
- URN
-
urn:nbn:de:101:1-2018092810062298799277
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:40 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Asamer, Eva
- Szkandera, Joanna
- Gibiser, Paul
- Lembeck, Anna Lena
- Stojakovic, Tatjana
- Kornprat, Peter
- Lackner, Caroline
- Winder, Thomas
- Schlick, Konstantin
- Stöger, Herbert
- Gerger, Armin
- Pichler, Martin
- Stotz, Michael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis
RNA-binding proteins as important regulators of long non-coding RNAs in cancer
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer: a retrospective analysis
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Inflammation, phagocytosis and cancer: another step in the CD47 act
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
Involvement of the long noncoding RNA NEAT1 in carcinogenesis